Top news of the week: 23.05.2022.
Medicine
Health care
Allergy
Macular degeneration
Antibody
Biotechnology
Healthcare
We cultivate the European life sciences innovation ecosystem, aiming to enable entrepreneurs to create transformational healthcare solutions. To celebrate our collaborations, we’ve put the spotlight on our innovation network in EMEA.
See more: https://t.co/ho5qKdWoir https://t.co/X5TuBjyplM
Open
Powering a secure biomedical data ecosystem
As a virtual resident company of JLABS @ BE, Apheris accesses mentorship from Johnson & Johnson data sciences leaders globally, broadening their understanding of data science …
A Path Forward for More Biotech Workers. Intriguing apprenticeship program for biomanufacturing technicians & clinical trial associates from @MassBioEd. https://t.co/8lDSjAZW8b
Open
A Path Forward for More Biotech Workers
Biotech needs more workers. More people who don’t have PhDs and MDs. The industry is 40 years old, and maturing. More companies are developing commercial products. Someone needs to make ...
To answer that question, expanded testing is needed that can determine levels of T immune cells https://t.co/sV10SUkKBL
Open
What Does ‘Protection’ against COVID Really Mean?
To answer that question, expanded testing is needed that can determine levels of T immune cells
An interesting take on the Sabatini situation. Positions it as a consensual relationship w/ someone who wasn’t a direct report + some networking events. Had to have been more there to warrant actions. Haven’t read the 200+ pg report @PeterAttiaMD https://t.co/LxlTfpwPYq
Open
He Was a World-Renowned Cancer Researcher. Now's He's Collecting Unemployment.
Behind the fall of David Sabatini, 'one of the greatest scientists' of his generation.
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted ROTH.
Clinical Catalysts for Biotech's Stock On Track for Mid 2022: https://t.co/enRy3r0GGG
$UBX #biotech @UnityBiotech
OpenClinical Catalysts for Biotech's Stock On Track for Mid 2022 Research Report
Upcoming potential stock-moving events include new data on the company's lead drug candidate for age-related eye diseases, noted a ROTH Capital Partners report.